A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3
18+
15 sites in CA, CT, FL +7
About this study
This Phase 3 study is testing Teclistamab in people with multiple myeloma. The primary outcome being measured is Overall Response Rate (ORR).
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
teclistamab
Primary: Overall Response Rate (ORR), Progression-Free Survival (PFS)
Secondary: Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by European Organization for Research and Treatment of Cancer Quality of life Questionnaire Core 30 (EORTC-QLQ-C30) Score, Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by European Quality of Life 5-Dimensions 5-Level Version (EQ-5D-5L) Score, Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Score, Complete Response (CR) or Better, Duration of Response (DoR), MRD-negative CR at 9 months, Minimal Residual Disease (MRD)-negative CR, Number of Participants With Treatment-Emergent Adverse Events (TEAE) by Severity
Oncology